Use of integrative epigenetic and cytogenetic analyses to identify novel tumor-suppressor genes in malignant melanoma

Melanoma Research

Volumn 21, Issue 4, 2011, Pages 298-307

  Mithani, Suhail K ^a   Smith, Ian M ^a   Califano, Joseph A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

DNA hypermethylation; epigenetics; malignant melanoma; tumor suppressor

Indexed keywords

CELL DNA; CHORDIN LIKE 1 PROTEIN; LIPOPROTEIN LIPASE; PHOSPHATIDYLINOSITOL SPECIFIC PHOSPHOLIPASE C X DOMAIN CONTAINING 1 PROTEIN; RETINOIC ACID RECEPTOR RESPONDER 1 PROTEIN; RNA; SECRETED FRIZZLED RELATED PROTEIN 1; TRANSMEMBRANE PROTEIN 47; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN 22;

ADULT; AGED; ARTICLE; CHROMOSOME ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENE DELETION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC TRANSFECTION; GENOME ANALYSIS; HUMAN; HUMAN CELL; MALE; MELANOMA; METHYLATION; MICROARRAY ANALYSIS; NEVUS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; AZACITIDINE; CELL LINE, TUMOR; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; EPIGENESIS, GENETIC; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENOMICS; HUMANS; MALE; MELANOMA; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SKIN NEOPLASMS; TRANSFECTION;

EID: 79960714772     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328344a003     Document Type: Article

References (59)

1. Muthusamy V, Duraisamy S, Bradbury CM, Hobbs C, Curley DP, Nelson B, Bosenberg M. Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res 2006; 66:11187-11193. (Pubitemid 46009946)
2. Liu S, Ren S, Howell P, Fodstad O, Riker AI. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res 2008; 21:545-558.
3. Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res 2007; 67:2632-2642. (Pubitemid 46548950)
4. Schwabe M, Lubbert M. Epigenetic lesions in malignant melanoma. Curr Pharm Biotechnol 2007; 8:382-387. (Pubitemid 350268197)
5. Strauss BS. Limits to the human cancer genome project? Science 2007; 315:762-764.
6. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005; 436:117-122. (Pubitemid 40966196)
7. Garraway LA, Weir BA, Zhao X, Widlund H, Beroukhim R, Berger A, et al. 'Lineage addiction' in human cancer: lessons from integrated genomics. Cold Spring Harb Symp Quant Biol 2005; 70:25-34. (Pubitemid 44124854)
8. Shen L, Kondo Y, Ahmed S, Boumber Y, Konishi K, Guo Y, et al. Drug sensitivity prediction by Cp G island methylation profile in the NCI-60 cancer cell line panel. Cancer Res 2007; 67:11335-11343. (Pubitemid 350248560)
9. Pujana MA, Ruiz A, Badenas C, Puig-Butille JA, Nadal M, Stark M, et al. Molecular characterization of a t(9;12)(p21;q13) balanced chromosome translocation in combination with integrative genomics analysis identifies C9orf14 as a candidate tumor-suppressor. Genes Chromosomes Cancer 2007; 46:155-162. (Pubitemid 44913380)
10. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 2006; 66:6050-6062.
11. Dahia PL, Hao K, Rogus J, Colin C, Pujana MA, Ross K, et al. Novel pheochromocytoma susceptibility loci identified by integrative genomics. Cancer Res 2005; 65:9651-9658. (Pubitemid 41541440)
12. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 2005; 11:7234-7242. (Pubitemid 41507680)
13. Baudis M, Cleary ML. http://www.progenetix.com: an online repository for molecular cytogenetic aberration data. Bioinformatics 2001; 17:1228-1229. (Pubitemid 33735351)
14. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of Cp G islands. Proc Natl Acad Sci USA 1996; 93:9821-9826. (Pubitemid 26296693)
15. Li LC, Dahiya R. Meth Primer: designing primers for methylation PCRs. Bioinformatics 2002; 18:1427-1431. (Pubitemid 35414532)
16. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135-2147. (Pubitemid 41653105)
17. Glazer CA, Smith IM, Ochs MF, Begum S, Westra W, Chang SS, et al. Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC. PLoS One 2009; 4:e8189.
18. Smith IM, Glazer CA, Mithani SK, Ochs MF, Sun W, Bhan S, et al. Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One 2009; 4:4961.
19. Bonazzi VF, Irwin D, Hayward NK. Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma. Genes Chromosomes Cancer 2009; 48:10-21.
20. Sakuta H, Suzuki R, Takahashi H, Kato A, Shintani T, Iemura Si, et al. Ventroptin: a BMP-4 antagonist expressed in a double-gradient pattern in the retina. Science 2001; 293:111-115. (Pubitemid 32625506)
21. Kane R, Godson C, O'Brien C. Chordin-like 1, a bone morphogenetic protein-4 antagonist, is upregulated by hypoxia in human retinal pericytes and plays a role in regulating angiogenesis. Mol Vis 2008; 14:1138-1148. (Pubitemid 351917369)
22. Kosinski C, Li VS, Chan AS, Zhang J, Ho C, Tsui WY, et al. Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad Sci USA 2007; 104:15418-15423. (Pubitemid 47502932)
23. Cheung IY, Feng Y, Danis K, Shukla N, Meyers P, Ladanyi M, Cheung NK. Novel markers of subclinical disease for Ewing family tumors from gene expression profiling. Clin Cancer Res 2007; 13:6978-6983. (Pubitemid 350276878)
24. Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, Brunet JP, et al. Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res 2008; 6:760-769.
25. Gao Y, Kobayashi H, Ganss B. The human KROX-26/ZNF22 gene is expressed at sites of tooth formation and maps to the locus for permanent tooth agenesis (He-Zhao deficiency). J Dent Res 2003; 82:1002-1007. (Pubitemid 41713820)
26. Liu W, Wang H, Zhao S, Zhao W, Bai S, Zhao Y, et al. The novel gene locus for agenesis of permanent teeth (He-Zhao deficiency) maps to chromosome 10q11.2. J Dent Res 2001; 80:1716-1720. (Pubitemid 32931345)
27. Ko J, Ryu KS, Lee YH, Na DS, Kim YS, Oh YM, et al. Human secreted frizzled-related protein is down-regulated and induces apoptosis in human cervical cancer. Exp Cell Res 2002; 280:280-287. (Pubitemid 35333769)
28. Melkonyan HS, Chang WC, Shapiro JP, Mahadevappa M, Fitzpatrick PA, Kiefer MC, et al. SARPs: a family of secreted apoptosis-related proteins. Proc Natl Acad Sci USA 1997; 94:13636-13641.
29. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004; 36:417-422. (Pubitemid 38437267)
30. Leach RJ, Banga SS, Ben-Othame K, Chughtai S, Clarke R, Daiger SP, et al. Report of the third international workshop on human chromosome 8 mapping. San Antonio, Texas, October 25-27, 1996. Cytogenet Cell Genet 1996; 75:71-84. (Pubitemid 27073148)
31. Klopocki E, Kristiansen G, Wild PJ, Klaman I, Castanos-Velez E, Singer G, et al. Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol 2004; 25:641-649.
32. Ugolini F, Adelaide J, Charafe-Jauffret E, Nguyen C, Jacquemier J, Jordan B, et al. Differential expression assay of chromosome arm 8p genes identifies frizzled-related (FRP1/FRZB) and fibroblast growth factor receptor 1 (FGFR1) as candidate breast cancer genes. Oncogene 1999; 18:1903-1910. (Pubitemid 29145858)
33. Ugolini F, Charafe-Jauffret E, Bardou VJ, Geneix J, Adélaïde J, Labat-Moleur F, et al. WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene 2001; 20:5810-5817. (Pubitemid 32937950)
34. Armes JE, Hammet F, de Silva M, Ciciulla J, Ramus SJ, Soo WK, et al. Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers. Oncogene 2004; 23:5697-5702. (Pubitemid 39093049)
35. Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P, et al. The Wnt antagonist s FRP1 in colorectal tumorigenesis. Cancer Res 2004; 64:883-888. (Pubitemid 38176888)
36. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, Van Engeland M, Weijenberg MP, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31:141-149.
37. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005; 65:4218-4227. (Pubitemid 40775660)
38. Takada T, Yagi Y, Maekita T, Imura M, Nakagawa S, Tsao SW, et al. Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers. Cancer Sci 2004; 95:741-744. (Pubitemid 39335094)
39. Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg RC, Klopocki E, et al. Deletions of chromosome 8p and loss of s FRP1 expression are progression markers of papillary bladder cancer. Lab Invest 2004; 84:465-478. (Pubitemid 41656474)
40. To KF, Chan MW, Leung WK, Yu J, Tong JH, Lee TL, et al. Alterations of frizzled (Fz E3) and secreted frizzled related protein (hs FRP) expression in gastric cancer. Life Sci 2001; 70:483-489. (Pubitemid 34017541)
41. Fukui T, Kondo M, Ito G, Maeda O, Sato N, Yoshioka H, et al. Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hyper-methylation in non-small-cell lung cancer. Oncogene 2005; 24:6323-6327. (Pubitemid 43080055)
42. Mutoh M, Niho N, Wakabayashi K. Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice. Biol Chem 2006; 387:381-385.
43. Niho N, Mutoh M, Takahashi M, Tsutsumi K, Sugimura T, Wakabayashi K. Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice. Proc Natl Acad Sci USA 2005; 102:2970-2974. (Pubitemid 40299900)
44. Kota RS, Ramana CV, Tenorio FA, Enelow RI, Rutledge JC. Differential effects of lipoprotein lipase on tumor necrosis factor-alpha and interferon-gamma-mediated gene expression in human endothelial cells. J Biol Chem 2005; 280:31076-31084. (Pubitemid 41291842)
45. Schwarz S, Hufnagel B, Dworak M, Klumpp S, Krieglstein J. Protein phosphatase type 2Calpha and 2Cbeta are involved in fatty acid-induced apoptosis of neuronal and endothelial cells. Apoptosis 2006; 11:1111-1119. (Pubitemid 44035960)
46. Gallucci M, Merola R, Farsetti A, Orlandi G, Sentinelli S, De Carli P, et al. Cytogenetic profiles as additional markers to pathological features in clinically localized prostate carcinoma. Cancer Lett 2006; 237:76-82.
47. Liu CJ, Lin SC, Chen YJ, Chang KM, Chang KW. Array-comparative genomic hybridization to detect genomewide changes in microdissected primary and metastatic oral squamous cell carcinomas. Mol Carcinog 2006; 45:721-731.
48. Baffa R, Santoro R, Bullrich F, Mandes B, Ishii H, Croce CM. Definition and refinement of chromosome 8p regions of loss of heterozygosity in gastric cancer. Clin Cancer Res 2000; 6:1372-1377. (Pubitemid 30226222)
49. Cunningham C, Dunlop MG, Wyllie AH, Bird CC. Deletion mapping in colorectal cancer of a putative tumour suppressor gene in 8p22-p21.3. Oncogene 1993; 8:1391-1396. (Pubitemid 23129865)
50. Kim JW, Cheng Y, Liu W, Li T, Yegnasubramanian S, Zheng SL, et al. Genetic and epigenetic inactivation of LPL gene in human prostate cancer. Int J Cancer 2009; 124:734-738.
51. Nagpal S, Patel S, Asano AT, Johnson AT, Duvic M, Chandraratna RA. Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin. J Invest Dermatol 1996; 106:269-274. (Pubitemid 26096423)
52. Rambow F, Malek O, Geffrotin C, Leplat JJ, Bouet S, Piton G, et al. Identification of differentially expressed genes in spontaneously regressing melanoma using the Me Li M swine model. Pigment Cell Melanoma Res 2008; 21:147-161. (Pubitemid 351551222)
53. Jing C, El-Ghany MA, Beesley C, Foster CS, Rudland PS, Smith P, Ke Y. Tazarotene-induced gene 1 (TIG1) expression in prostate carcinomas and its relationship to tumorigenicity. J Natl Cancer Inst 2002; 94:482-490. (Pubitemid 34411286)
54. Shutoh M, Oue N, Aung PP, Noguchi T, Kuraoka K, Nakayama H, et al. DNA methylation of genes linked with retinoid signaling in gastric carcinoma: expression of the retinoid acid receptor beta, cellular retinol-binding protein 1, and tazarotene-induced gene 1 genes is associated with DNA methylation. Cancer 2005; 104:1609-1619. (Pubitemid 41437423)
55. Youssef EM, Chen XQ, Higuchi E, Kondo Y, Garcia-Manero G, Lotan R, Issa JP. Hypermethylation and silencing of the putative tumor suppressor tazarotene-induced gene 1 in human cancers. Cancer Res 2004; 64:2411-2417. (Pubitemid 38523894)
56. Scatolini M, Grand MM, Grosso E, Venesio T, Pisacane A, Balsamo A, et al. Altered molecular pathways in melanocytic lesions. Int J Cancer 2010; 126:1869-1881.
57. Smith AP, Hoek K, Becker D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther 2005; 4:1018-1029. (Pubitemid 41598600)
58. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 2006; 98:472-482.
59. Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, Greally J, Verma A. Aberrant DNA methylation in malignant melanoma. Melanoma Res 2010; 20:253-265.